JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vanhauwe, J. F. M.
Right arrow Articles by Leysen, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanhauwe, J. F. M.
Right arrow Articles by Leysen, J. E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 295, Issue 1, 274-283, October 2000

G-Protein Sensitivity of Ligand Binding to Human Dopamine D2 and D3 Receptors Expressed in Escherichia coli: Clues for a Constrained D3 Receptor Structure1

Jurgen F. M. Vanhauwe2 , Katty Josson, Walter H. M. L. Luyten, Arnold J. Driessen and Josée E. Leysen

Department of Biochemical Pharmacology (J.F.M.V., K.J., J.E.L.), and Department of Functional Genomics (W.H.M.L.L.), Janssen Research Foundation, Belgium; and Department of Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, The Netherlands (A.J.D.)

Human dopamine D2 and D3 receptors were expressed in Chinese hamster ovary (CHO) and Escherichia coli cells to compare their ligand binding properties in the presence or absence of G-proteins and to analyze their ability to interact with Gi/o-proteins. Binding affinities of agonists (dopamine, 7-OH-DPAT, PD128907, lisuride) and antagonists/inverse agonists (haloperidol, risperidone, domperidone, spiperone, raclopride, nemonapride), measured using [125I]iodosulpride and [3H]7-OH-DPAT, were similar for hD3 receptors in E. coli and CHO cell membranes. Both agonists and antagonists showed 2- to 25-fold lower binding affinities at hD2 receptors in E. coli versus CHO cell membranes (measured with [3H]spiperone), but the rank order of potencies remained similar. Purported inverse agonists did not display higher affinities for G-protein-free receptors. In CHO membranes, GppNHp decreased high affinity agonist ([3H]7-OH-DPAT) binding at hD2 receptors but not at hD3 receptors. Also, [3H]7-OH-DPAT (nanomolar concentration range) binding was undetectable at hD2 but clearly measurable at hD3 receptors in E. coli membranes. Addition of a Gi/o-protein mix to E. coli membranes increased high affinity [3H]7-OH-DPAT binding in a concentration-dependent manner at hD2 and hD3 receptors; this effect was reversed by addition of GppNHp. The potency of the Gi/o-protein mix to reconstitute high affinity binding was similar for hD2 and hD3 receptors. Thus, agonist binding to D3 receptors is only slightly affected by G-protein uncoupling, pointing to a rigid receptor structure. Furthermore, we propose that the generally reported lower signaling capacity of D3 receptors (versus D2 receptors) is not due to its lower affinity for G-proteins but attributed to its lower capacity to activate these G-proteins.


1 This work was supported by a grant (project IWT 940232) from the IWT (Vlaams Instituut voor de Bevordering van het Wetenschappelijk-Technologisch Onderzoek in de Industrie).

2 Present address: the laboratory of Dr. Heidi Hamm, Northwestern University, Institute of Neuroscience, Chicago, IL.


0022-3565/00/2951-0274$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.